Coronary artery disorder
Therapeutic area
Cardiology
Rare disease
No
- Definition
- Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Coronary artery disorder
- Therapeutic area
- Cardiology
- coronary artery disorder
- CAD
- CHD (coronary heart disease)
- coronary artery disease
- coronary artery disease or disorder
- coronary disease
- coronary heart disease
- disease of coronary artery
- disease or disorder of coronary artery
- disorder of coronary artery
- coronary arteriosclerosis
- Severity
- Severe
- Cardiology
- Vascular Medicine
- MONDO ID
- MONDO:0005010
- Parent condition
- MONDO:0000473
Related records
Broader conditions (7)
- Arterial disorder
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Heart disorder
- Human disease
- Vascular disorder
Narrower conditions (25)
- Abnormal number of coronary ostia
- Anomalous left coronary artery from the pulmonary artery
- Aortopulmonary coronary arterial course
- Arteriolosclerosis
- Arteriosclerosis obliterans
- Congenital coronary artery aneurysm
- Coronary aneurysm
- Coronary arterial fistulas
- Coronary artery congenital malformation
- Coronary artery disease, autosomal dominant 2
- Coronary artery disease, autosomal dominant, 1
- Coronary artery intramyocardial course
- Coronary atherosclerosis
- Coronary restenosis
- Coronary stenosis
- Coronary thrombosis
- Coronary vasospasm
- Fibromuscular dysplasia of the coronary arteries
- Intermediate coronary syndrome
- Intramural coronary arterial course
Trials (5,952)
- "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"
- "Erectile Function After PCI in MI and Non-MI Patients"
- "Expert IVUS-Eye" vs. IVUS-guided Left Main Bifurcation PCI
- "Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study"
- "JACTAX" Trial Drug Eluting Stent Trial
- "L-Sandwich" Strategy in the True Coronary Bifurcation Lesions
- "Nutrition Education by Nurses in Patients After Coronary Artery Bypass Grafting: Effect on Patients' Dietary Pattern, Adherence and Clinical Outcomes"
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- "Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"
- "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
- "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
- "The Effect of Virtual Visitation in the Intensive Care Unit on Pain, Anxiety, and Sleep Levels"
- "TransRadial Ultra Support Technique" (TRUST)
- (A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
- (EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials
- 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTORâ„¢) in Combination With Ezetimibe
- 123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients
- 123I-mIBG SPECT Imaging
Approved drugs (24)
- Alirocumab
- Amlodipine besylate
- Ammonia N 13
- Aspirin
- Atorvastatin calcium
- Bempedoic acid
- Dipyridamole
- Evolocumab
- Gemfibrozil
- Isosorbide dinitrate
- Isosorbide mononitrate
- Lovastatin
- Niacin
- Nitroglycerin
- Perindopril erbumine
- Pravastatin sodium
- Ramipril
- Rivaroxaban
- Rosuvastatin calcium
- Rubidium chloride RB 82
Drugs in development (181)
- Acarbose Phase 3
- Acetylcholine Phase 1
- Acetylcysteine Phase 3
- Adenosine Phase 2
- Alanine Phase 3
- Alanyl glutamine Phase 3
- Alteplase Phase 3
- Amiloride Phase 2
- Amiodarone Early phase 1
- Amlodipine Phase 3
- Anacetrapib Phase 3
- Anivamersen Phase 3
- Anpocogin Phase 2
- Apabetalone Phase 3
- Apadenoson Phase 3
- Argatroban Phase 2
- Arginine Phase 1
- Ascorbic acid Phase 3
- Atopaxar Phase 2
- Atorvastatin Phase 3
Other linked drugs (21)
- Abciximab
- Ammonia solution, strong
- Antithrombin gamma
- Arbutamine
- Dabigatran
- Darapladib
- Fendiline
- Iodixanol
- Isoproterenol
- Maritime pine
- Midazolam
- Montelukast
- Omega-3-acid ethyl esters
- Omeprazole
- Probucol
- Regadenoson
- Remimazolam
- Rubidium RB-82
- Sulfasalazine
- Varenicline